Watanabe D - Search Results

1

Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer.

Watanabe D, Fujii H, Matsuhashi N, Iihara H, Yamada Y, Ishihara T, Takahashi T, Yoshida K, Suzuki A. Watanabe D, et al. Anticancer Res. 2020 Apr;40(4):2379-2386. doi: 10.21873/anticanres.14207. Anticancer Res. 2020. PMID: 32234941

2

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.

Fujii H, Yamada Y, Watanabe D, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A. Fujii H, et al. Among authors: watanabe d. Cancer Chemother Pharmacol. 2019 Jan;83(1):123-129. doi: 10.1007/s00280-018-3711-8. Epub 2018 Oct 30. Cancer Chemother Pharmacol. 2019. PMID: 30377777 Free PMC article.

3

Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy.

Yamada Y, Fujii H, Watanabe D, Kato-Hayashi H, Ohata K, Kobayashi R, Ishihara T, Uemura S, Iwashita T, Shimizu M, Suzuki A. Yamada Y, et al. Among authors: watanabe d. Cancers (Basel). 2018 Nov 16;10(11):454. doi: 10.3390/cancers10110454. Cancers (Basel). 2018. PMID: 30453583 Free PMC article.

4

High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy.

Yamada Y, Fujii H, Ohata K, Kato-Hayashi H, Watanabe D, Ishihara T, Uemura S, Iwashita T, Imai H, Matsuhashi N, Takahashi T, Sugiyama T, Shimizu M, Yoshida K, Suzuki A. Yamada Y, et al. Among authors: watanabe d. Med Oncol. 2019 Jun 3;36(7):63. doi: 10.1007/s12032-019-1288-7. Med Oncol. 2019. PMID: 31161433

5

Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin.

Watanabe D, Fujii H, Yamada Y, Iihara H, Ishihara T, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A. Watanabe D, et al. Anticancer Res. 2020 Jan;40(1):299-304. doi: 10.21873/anticanres.13953. Anticancer Res. 2020. PMID: 31892580

6

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.

Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, Yamada Y, Watanabe D, Ishihara T, Suzuki A, Yoshida K. Fujii H, et al. Among authors: watanabe d. Oncologist. 2020 Mar;25(3):e469-e476. doi: 10.1634/theoncologist.2019-0541. Epub 2019 Nov 20. Oncologist. 2020. PMID: 32162797 Free PMC article.

7

Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept.

Yamada Y, Matsuhashi N, Fujii H, Makiyama A, Iihara H, Takahashi T, Watanabe D, Kiyama S, Kobayashi R, Suzuki A, Yoshida K. Yamada Y, et al. Among authors: watanabe d. Anticancer Res. 2021 Jan;41(1):533-541. doi: 10.21873/anticanres.14805. Anticancer Res. 2021. PMID: 33419853

8

Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib.

Watanabe D, Fujii H, Yamada Y, Matsuhashi N, Makiyama A, Iihara H, Takahashi T, Kiyama S, Kobayashi R, Yoshida K, Suzuki A. Watanabe D, et al. Int J Clin Oncol. 2021 Jul;26(7):1257-1263. doi: 10.1007/s10147-021-01910-2. Epub 2021 Apr 11. Int J Clin Oncol. 2021. PMID: 33839963

9

Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy.

Fujii H, Ueda Y, Hirose C, Ohata K, Sekiya K, Kitahora M, Sadaka S, Yamamoto S, Watanabe D, Kato-Hayashi H, Iihara H, Kobayashi R, Kaburaki M, Matsuhashi N, Takahashi T, Makiyama A, Yoshida K, Hayashi H, Suzuki A. Fujii H, et al. Among authors: watanabe d. J Pharm Health Care Sci. 2022 Mar 2;8(1):8. doi: 10.1186/s40780-022-00239-w. J Pharm Health Care Sci. 2022. PMID: 35236407 Free PMC article.

10

One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis.

Watanabe D, Iihara H, Fujii H, Makiyama A, Nishida S, Suzuki A. Watanabe D, et al. Oncologist. 2022 Jun 8;27(6):e524-e532. doi: 10.1093/oncolo/oyac060. Oncologist. 2022. PMID: 35427418 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

879 results

Search Page